A drug approved for the treatment of rheumatoid arthritis may also turn out to be the first targeted therapy for one of the most common forms of kidney disease, a condition that almost inevitably leads to kidney failure. A team led by Massachusetts General Hospital (MGH) researchers is reporting that treatment with abatacept (Orencia) appeared to halt the course of focal segmental glomerulosclerosis (FSGS) in five patients, preventing four from losing transplanted kidneys and achieving disease remission in the fifth. The report is being issued online in the New England Journal of Medicine to coincide with a presentation at the American Society for Nephrology annual meeting.
Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label focal segmental glomerulosclerosis (FSGS). Show all posts
Showing posts with label focal segmental glomerulosclerosis (FSGS). Show all posts
Friday, December 20, 2013
Subscribe to:
Posts (Atom)